22 completed, 7 recruiting, 6 unknown, 5 active not recruiting. 51 Phase 2, 10 Phase 1.
Follow Frontotemporal Lobar Degeneration: new trials by email Literature Review of Frontotemporal Lobar Degeneration trials Research Report on Frontotemporal Lobar Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alzheimer's Tau Platform: Regimen A - AADvac1 AADvac1, Donanemab - Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease | Phase 2 | Enrolling by invitation | Paul S. Aisen | 450 | 2026-11-03 | 2026-10-26 |
| A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies NIO752, Placebo - Progressive Supranuclear Palsy, Corticobasal Degeneration | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 48 | 2026-10-23 | 2026-10-09 |
| The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1 AADvac1, Matching Placebo - PSP - Progressive Supranuclear Palsy | Phase 2 | Enrolling by invitation | Adam Boxer | 146 | 2026-07-29 | 2026-11-05 |
| The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31 LM11A-31, Matching Placebo - PSP - Progressive Supranuclear Palsy | Phase 2 | Enrolling by invitation | Adam Boxer | 147 | 2026-07-29 | 2026-11-05 |
| MSC-Exosome Therapy for Frontotemporal Dementia Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes （Low-Dose）, Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes （High-Dose）, Placebo Comparator (0.9% NaCl) - Frontotemporal Dementia | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 33 | 2026-07-01 | 2026-07-13 |
| Daridorexant for Alzheimer Disease Prevention Daridorexant 50 mg, Placebo - Alzheimer Disease (AD) | Phase 2 | Recruiting | Douglas Mental Health University Institute | 240 | 2025-10-14 | 2025-12-19 |
| Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia Neflamapimod, Placebo - Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Phase 2 | Active not recruiting | EIP Pharma Inc | 20 | 2025-10-02 | 2026-07-06 |
| Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia NS101 IV infusion, Placebo IV Infusion - Dementia Frontotemporal | Phase 2 | Not yet recruiting | Hee-Jin Kim | 15 | 2025-10-01 | 2025-09-04 |
| A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia. Lemborexant 10 MG, Placebo - Insomnia | Phase 2 | Recruiting | Woolcock Institute of Medical Research | 20 | 2025-05-13 | 2026-09-18 |
| Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia Vortioxetine - Fronto-temporal Dementia, Fronto-temporal Lobar Dementia | Phase 2 | Recruiting | Johns Hopkins University | 50 | 2025-03-20 | 2026-03-09 |
| Communication Bridge 3 Study Communication Bridge™, Evidence-Based Impairment Focused - Primary Progressive Aphasia | Phase 2 | Recruiting | University of Chicago | 200 | 2024-08-23 | 2026-06-01 |
| Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia Active tDCS + Language Therapy, Sham tDCS + Language Therapy - Primary Progressive Aphasia, Logopenic Progressive Aphasia | Phase 2 | Recruiting | Johns Hopkins University | 180 | 2024-02-13 | 2026-05-05 |
| A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101 - Frontotemporal Dementia, FTD | Phase 1 / Phase 2 | Recruiting | AviadoBio Ltd | 18 | 2023-08-30 | 2026-08-13 |
| Nabilone for Agitation in Frontotemporal Dementia Nabilone, Placebo - Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant | Phase 2 | Terminated | Simon Ducharme, MD | 3 | 2023-03-07 | 2026-07-28 |
| Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) WVE-004 10 mg Q12W - Amyotrophic Lateral Sclerosis, Frontotemporal Dementia | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 8 | 2022-12-14 | 2026-09-09 |
| Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study) Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP - Cognitively Normal Older Adults, Hypertension | Phase 2 | Active not recruiting | Rong Zhang | 180 | 2022-10-25 | 2026-07-21 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) DNL593, Placebo - Frontotemporal Dementia | Phase 1 / Phase 2 | Active not recruiting | Denali Therapeutics Inc. | 85 | 2022-02-01 | 2026-01-15 |
| First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia [18F]RP-115 PET/MRI or PET/CT and MRI - Alzheimer Disease, Frontotemporal Dementia | Phase 1 / Phase 2 | Recruiting | David Wilson | 102 | 2021-11-02 | 2025-04-17 |
| A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD TPN-101, 400 mg/day, Placebo - Amyotrophic Lateral Sclerosis, Frontotemporal Dementia | Phase 2 | Completed | Transposon Therapeutics, Inc. | 42 | 2021-10-01 | 2026-04-03 |
| A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease LY3372689, Placebo - Alzheimer Disease | Phase 2 | Completed | Eli Lilly and Company | 327 | 2021-09-16 | 2026-06-12 |
Showing 20 of 51. Sign in to see all of them.
Frontotemporal Dementia (35) · Pick Disease of the Brain (22) · Alzheimer Disease (15) · Dementia (11) · Aphasia, Primary Progressive (6) · Cognitive Dysfunction (5) · Plaque, Amyloid (5) · Amyotrophic Lateral Sclerosis (4) · Neurodegenerative Diseases (4) · Supranuclear Palsy, Progressive (4) · Tauopathies (4) · Aphasia (3) · Nervous System Diseases (3) · Brain Diseases (2)
Brain Diseases (49) · Central Nervous System Diseases (49) · Mental Disorders (49) · Neurocognitive Disorders (49) · Nervous System Diseases (48) · Neurodegenerative Diseases (44) · Dementia (40) · Nutritional and Metabolic Diseases (40) · Metabolic Diseases (39) · Proteostasis Deficiencies (37) · TDP-43 Proteinopathies (37) · Pathological Conditions, Signs and Symptoms (20) · Tauopathies (16) · Frontotemporal Dementia (15)
florbetapir (4) · AADvac1 (3) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (2) · Lithium (2) · Magnetic Resonance Spectroscopy (2) · Memantine (2) · Oxytocin (2) · Sugars (2) · THK5351 (2) · Amlodipine (1) · Angiotensin Receptor Antagonists (1) · Calcium Channel Blockers (1) · Diffusion Tensor Imaging (1) · FRM-0334 (1) · Fluorodeoxyglucose F18 (1)
Chang Gung Memorial Hospital (4) · Columbia University (4) · Adam Boxer (2) · I.R.C.C.S. Fondazione Santa Lucia (2) · Johns Hopkins University (2) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · AbbVie (1) · Alector Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · AviadoBio Ltd (1) · Avid Radiopharmaceuticals (1) · Axon Neuroscience SE (1) · Brigham and Women's Hospital (1) · David Wilson (1)
United States (31) · Canada (10) · United Kingdom (9) · Italy (7) · Belgium (6) · France (6) · Netherlands (6) · Australia (5) · Spain (5) · Taiwan (4) · Germany (3) · Poland (3) · Sweden (3) · Brazil (2) · Czechia (2)
Adam Boxer, MD, PhD (3) · Edward Huey, MD (3) · Anne-Marie Wills, MD (2) · Irene Litvan, MD (2) · Julio Rojas-Martinez, MD, PhD (2) · Alessandro Martorana, MD, PhD (1) · Amy Berger, MD (1) · Anne Sophie Rigaud, MD (1) · Bernard Laurent, MD (1) · Bernard-Francois Michel, MD (1) · Brendon Yee, MBChB, FRACP, FCCP, PhD (1) · Bruno Dubois, MD (1) · Camilla Hoyos, MPH, PhD (1)
PMID 21157021, PMID 22922703, PMID 30261917, PMID 31834916, PMID 32963103, PMID 34057284, PMID 34559230, PMID 34815790, PMID 35184428, PMID 35260178, PMID 37624739, PMID 38018119, PMID 38745011, PMID 39580468, PMID 39862881, PMID 40368603, PMID 40809903, PMID 41281734, PMID 42441396
2016 (2), 2023 (2), R01AG085029 (2), 2014 (1), 2015 (1), K23AG088248 (1), R00NS060766 (1), R01AG050440 (1), R01AG055299 (1), R01AG055425 (1), R01AG075111 (1), R01AG076660 (1), R01AG078457 (1), R01NS076837 (1), RF1AG051556 (1)